The Polyp Prevention Trial I: Rationale, design, recruitment, and baseline participant characteristics

Arthur Schatzkin, Elaine Lanza, Laurence S. Freedman, Joseph Tangrea, M. Robert Cooper, James R. Marshall, Patricia A. Murphy, Joseph V. Selby, Moshe Shike, Robert R. Schade, Randall W. Burt, J. Walter Kikendall, Jack Cahill

Research output: Contribution to journalArticlepeer-review

92 Scopus citations

Abstract

The Polyp Prevention Trial (PPT) is a multicenter randomized controlled trial examining the effect of a low-fat (20% of total energy intake), high- fiber (18 g/1000 kcal), high-vegetable and -fruit (5-8 daily servings) dietary pattern on the recurrence of adenomatous polyps of the large bowel, precursors of most colorectal malignancies. Eligibility criteria include one or more adenomas removed within 6 months of randomization; complete nonsurgical polyp removal and complete colonic examination to the cecum at the qualifying colonoscopy; age 35 years or more; no history of colorectal cancer, inflammatory bowel disease, or large bowel resection; and satisfactory completion of a food frequency questionnaire and 4-day food record. Of approximately 38,277 potential participants with one or more polyps recently resected, investigators at eight clinical centers randomized 2,079 (5.4%; 1,037 in the intervention and 1,042 in the control arm) between June 1991 and January 1994, making the PPT the largest adenoma recurrence trial ever conducted. Of PPT participants, 35% are women and 10% are minorities. At study entry, participants averaged 61.4 years of age; 14% of them smoked, and 22% used aspirin. At the baseline colonoscopy, 35% of participants had two or more adenomas, and 29% had at least one large (≥1 cm) adenoma. Demographic, behavioral, dietary, and clinical characteristics are comparable across the two study arms. Participants have repeat colonoscopies after 1 (T1) and 4 (T4) years of follow-up. The primary end point is adenoma recurrence; secondary end points include number, size, location, and histology of adenomas. All resected lesions are reviewed centrally by gastrointestinal pathologists. The trial provides 90% power to detect a reduction of 24% in the annual adenoma recurrence rate. The primary analytic period, on which sample size calculations were based, is 3 years (T1 to T4), which permits a 1-year lag time for the intervention to work and allows a more definitive clearing of lesions at T1, given that at least 10-15% of polyps may he missed at baseline. The final (T4) colonoscopies are expected to be completed in early 1998.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume5
Issue number5
StatePublished - May 1996
Externally publishedYes

Fingerprint

Dive into the research topics of 'The Polyp Prevention Trial I: Rationale, design, recruitment, and baseline participant characteristics'. Together they form a unique fingerprint.

Cite this